Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/105324
DC FieldValueLanguage
dc.contributor.authorCarvalho, Laura Sofia-
dc.contributor.authorGonçalves, Nélio-
dc.contributor.authorFonseca, Nuno André-
dc.contributor.authorMoreira, João Nuno-
dc.date.accessioned2023-02-17T09:14:45Z-
dc.date.available2023-02-17T09:14:45Z-
dc.date.issued2021-01-13-
dc.identifier.issn1424-8247pt
dc.identifier.urihttps://hdl.handle.net/10316/105324-
dc.description.abstractCancer, one of the most mortal diseases worldwide, is characterized by the gain of specific features and cellular heterogeneity. Clonal evolution is an established theory to explain heterogeneity, but the discovery of cancer stem cells expanded the concept to include the hierarchical growth and plasticity of cancer cells. The activation of epithelial-to-mesenchymal transition and its molecular players are widely correlated with the presence of cancer stem cells in tumors. Moreover, the acquisition of certain oncological features may be partially attributed to alterations in the levels, location or function of nucleolin, a multifunctional protein involved in several cellular processes. This review aims at integrating the established hallmarks of cancer with the plasticity of cancer cells as an emerging hallmark; responsible for tumor heterogeneity; therapy resistance and relapse. The discussion will contextualize the involvement of nucleolin in the establishment of cancer hallmarks and its application as a marker protein for targeted anticancer therapies.pt
dc.language.isoengpt
dc.publisherMDPIpt
dc.relationPOCI-01-0145-FEDER-016390pt
dc.relationCENTRO-01-0145- FEDER-000012-HealthyAging2020pt
dc.relationEuronanomed (FCT reference ENMed/0005/2015)pt
dc.relationUIDB/04539/2020pt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subjecttumor heterogeneitypt
dc.subjectdrug resistancept
dc.subjectcancer stem cellspt
dc.subjectnucleolinpt
dc.subjecttargeted therapiespt
dc.subjectepithelial-to-mesenchymal transitionpt
dc.titleCancer Stem Cells and Nucleolin as Drivers of Carcinogenesispt
dc.typearticle-
degois.publication.firstPage60pt
degois.publication.issue1pt
degois.publication.titlePharmaceuticalspt
dc.peerreviewedyespt
dc.identifier.doi10.3390/ph14010060pt
degois.publication.volume14pt
dc.date.embargo2021-01-13*
uc.date.periodoEmbargo0pt
item.fulltextCom Texto completo-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.openairetypearticle-
item.cerifentitytypePublications-
item.grantfulltextopen-
crisitem.project.grantnoCenter for Innovative Biomedicine and Biotechnology - CIBB-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
Appears in Collections:I&D CNC - Artigos em Revistas Internacionais
I&D CIBB - Artigos em Revistas Internacionais
Files in This Item:
Show simple item record

SCOPUSTM   
Citations

30
checked on Oct 14, 2024

WEB OF SCIENCETM
Citations

26
checked on Oct 2, 2024

Page view(s)

77
checked on Oct 15, 2024

Download(s)

28
checked on Oct 15, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons